Over the past five years, the Journal has published the results of several controlled trials of interferon alfa in the treatment of chronic viral hepatitis. The first three concerned hepatitis C1,2 and hepatitis B3; interferon alfa is now widely used for the treatment of these common diseases. In this issue, Farci and her colleagues report on the use of interferon alfa to treat chronic hepatitis D4. They note that 50 percent of the patients in their study who were treated with high doses of interferon (9 million units three times weekly) had a complete response, as defined . . .
No takes yet. Share an insight, caveat, or question.
Adrian M. Di Bisceglie (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: